Σάββατο 7 Αυγούστου 2010

Difficulties in "Letting Go" When Medicine Can Do Little More

From Medscape Medical News
Difficulties in "Letting Go" When Medicine Can Do Little More

Zosia Chustecka

August 3, 2010 — End-of-life discussions are difficult for doctors, a surgeon/writer admits in an essay entitled "Letting Go" that appeared in the August 2 issue of the New Yorker magazine.


There is a fine balancing act in these discussions between not killing hope and confronting other possibilities, including death. However, "talking about dying is enormously fraught," writes Atul Gawande, MD, a general and endocrine surgeon at Brigham and Women's Hospital in Boston, Massachusetts. He is also an associate professor of surgery at Harvard Medical School, and has been a staff writer at the magazine since 1998.

Many doctors admit to finding end-of-life discussions difficult, and often delay them, as previously reported by Medscape Medical News. It is an issue that many oncologists have to grapple with on a regular basis in their clinical practice, and it is regularly discussed in scientific journals and meetings. But in writing on the topic at length in the New Yorker, a magazine known for arts and cultural essays and humorous cartoons, Dr. Gawande brings the issue to a public forum.

In the article, he asks: "What should medicine do when it can't save your life?"

He illustrates the piece with several case histories. One patient was a young woman diagnosed with advanced lung cancer late in her first pregnancy. Although terminally ill, she was always optimistic that another treatment would help, and Dr. Gawande describes how he was "swept along by her optimism" and was unable to confront her with her likely grim prognosis.

"Doctors are especially hesitant to trample on a patient's expectation. You worry far more about being overly pessimistic than you do about being overly optimistic," he writes.

At the back of his mind was the "long tail of possibility" that this patient might be the one who defies the odds.

There is nothing wrong with such hope, he says, unless "it means we have failed to prepare for the outcome that is vastly more probable." In the case of the patient he was describing, this hope unfortunately left her and her family unprepared to deal with her death.

"We've created a multimillion-dollar edifice for dispensing the medical equivalent of lottery tickets — and have only the rudiments of a system to prepare patients for the near-certainty that those tickets will not win," he writes.

Issue Is Pressing and Expensive

"The issue has become pressing, in recent years, for reasons of expense," he points out. The terminally ill account for a lot of the soaring cost of healthcare — 25% of all Medicare spending goes toward the 5% of patients in their final year of life, and "most of that money goes for care in the last couple of months, which is of little apparent benefit."

Spending on cancer tends to follow a pattern, he notes. There are high initial costs as the cancer is treated, and then, if all goes well, these costs taper off.

For a breast cancer survivor, the average medical spend in 2003 was $54,000, most of it on the initial diagnosis, surgery, and where necessary radiation and chemotherapy.

However, for a patient with a fatal version of the disease, the cost curve is U-shaped, rising again toward the end, he points out. For a breast cancer patient with incurable disease, the average medical spend in the last 6 months of life was $63,000 in 2003.

"Our medical system is excellent at trying to stave off death with $8000-per-month chemotherapy, $3000-a-day intensive care, and $5000-an-hour surgery. Bt ultimately death comes, and no-one is very good at knowing when to stop."

When to Stop?

This question of when to stop is a modern problem, Dr. Gawande points out.

"For all but our most recent history, dying was typically a brief process. . . . The interval between recognizing that you had a life-threatening ailment and death was often just a matter of days or weeks."

"These days, swift catastrophic illness is the exception; for most people, death comes only after long medical struggle with an incurable condition — advanced cancer, progressive organ failure. . . . In all such cases, death is certain, but the timing isn't. So everyone struggles with this uncertainty — the how, and when, to accept that the battle is lost."

In the article, Dr. Gawande praises hospice care, and gives several examples of patients who greatly benefited from such care, including a young man with advanced pancreatic cancer. But he admits that all this was a revelation to him; his new understanding was gained first-hand after having accompanied a hospice nurse on her rounds.

Previously, he had equated hospice with "giving up" and a morphine drip, and he is certain that this view is shared by many doctors and patients.

In a live phone-in question-and-answer session with readers, a hospice worker commented on how patients and their caregivers often say "we wish we'd known about you sooner," and asks: "Shouldn't this be a wake-up for physicians? For the benefit of their patients and their patient's families?"

The hospice worker also noted that there appears to be a reluctance among physicians to discuss hospice with their patients, but at the same time there is an enthusiasm for "palliative care." The 2 are actually very similar, she pointed out: "What can we do to make physicians understand that hospice is just an extension of palliative care?"

Another person phoning in highlighted cultural differences, and described several scenarios in the Netherlands in which patients' wishes to stop treatment and die were respected. Dr. Gawande acknowledged the point, and wondered if there is more of a problem in the United States than elsewhere. He mentioned statistics from Sweden, where there has been a shift from around 90% to 30% in cancer patients dying in hospital over the past 2 decades, although he noted that some American centers have seen similar shifts in end-of life care.

"Fear of death (and facing death) seems to be a uniquely 20th century American problem," suggested one reader in an online commentary. "Why shouldn't there be continuous end-of-life discussions, held more casually during life's progression and not under the gun (if you will) at the end of one's life."

That reader criticized doctors for not being straightforward in discussing death, and called for more honesty. This was also a theme that emerged from a panel discussion at the National Comprehensive Cancer Network earlier this year, when experts urged "straight talk with compassion."

However, Dr. Gawande questioned whether these issues "are THAT culture-specific. I think it is common everywhere to come across people who hope against hope that they can be saved," and suggested that this is "just human nature."

"It seems to me that our job in medicine is to just deal with it. If we have to wait for people to stop yearning for the long tail — for the lottery ticket — in order to help them, we will be hurting a lot of people for a long time to come," Dr. Gawande said. "Instead, we need to become more effective in using the techniques that experts already have for walking people through these moments in their lives."

One way to improve is through training. "Experience alone does not produce improvement. You can communicate badly for 30 years," he pointed out.

"But deliberate practice with coaching makes for measurable improvements," he said. "And that's likely what we need in medicine. We train and retrain for surgical skills. We probably need to do so for these discussions with terminally ill patients, as well," he concluded.

Παρασκευή 6 Αυγούστου 2010

ERIBULIN FOR BREAST CANCER

J Clin Oncol. 2010 Aug 2. [Epub ahead of print]
Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine.
Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA.

Vall d'Hebron University Hospital, Barcelona, Spain; Weill Cornell Medical College, New York, NY; Baylor-Charles A. Sammons Cancer Center; Texas Oncology PA; US Oncology, Dallas; US Oncology, Houston, TX; Eisai Medical Research, Woodcliff Lake, NJ; Comprehensive Cancer Centers of Nevada, Henderson, NV; Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds; Eisai, London, United Kingdom; Centre de Lutte Contre le Cancer René Gauducheau, Nantes; Institut Claudius Régaud, Toulouse; Centre Léon Bérard, Lyon; Institut Paoli Calmettes, Marseille, France; Institut Jules Bordet, Université Libre de Bruxelles, Brussels; and University Hospital Gasthuisberg, Leuven, Belgium.
Abstract

PURPOSE The activity and safety of eribulin mesylate (E7389), a nontaxane microtubule dynamics inhibitor with a novel mechanism of action, were evaluated in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, taxane, and capecitabine. PATIENTS AND METHODS Eligible patients in this single-arm, open-label phase II study received eribulin mesylate (1.4 mg/m(2)) administered as a 2- to 5-minute intravenous infusion on days 1 and 8 of a 21-day cycle. The primary end point was objective response rate (ORR) assessed by independent review. Results Of 299 enrolled patients who had received a median of four prior chemotherapy regimens, 291 received eribulin (for a median of four cycles). Of these, 269 patients met key inclusion criteria for the primary efficacy analysis. The primary end point of ORR by independent review was 9.3% (95% CI, 6.1% to 13.4%; all partial responses [PRs]), the stable disease (SD) rate was 46.5%, and clinical benefit rate (complete response + PR + SD >/= 6 months) was 17.1%. The investigator-reported ORR was 14.1% (95% CI, 10.2% to 18.9%). Median duration of response was 4.1 months, and progression-free survival was 2.6 months. Median overall survival was 10.4 months. The most common treatment-related grade 3 or 4 toxicities were neutropenia (54%; febrile neutropenia, 5.5%), leukopenia (14%), and asthenia/fatigue (10%; no grade 4); grade 3 neuropathy occurred in 6.9% of patients (no grade 4). CONCLUSION Eribulin demonstrated antitumor activity in extensively pretreated patients who had previously received an anthracycline, taxane, and capecitabine, with a manageable tolerability profile.

A RARE TUMOR

Prog Urol. 2010 Jul;20(7):538-41. Epub 2010 Jan 6.
[Renal medullary carcinoma: remission with gemcitabine-cisplatin and review of therapeutic perspectives]

[Article in French]
Diao B, Paule B, Esquivel S, Abbou CC, Salomon L, De La Taille A.

Service d'urologie de l'hôpital Henri-Mondor, AP-HP, 51, avenue du Maréchal-de-Tassigny, 94010 Créteil, France. babacardiao104uro@yahoo.fr
Abstract

We report a case of renal medullary carcinoma concerning a 38-year-old woman. Heterozygote sickle cell trait was noticed in her past medical history. The physical examination was unremarkable. The CT-scan revealed a left renal mass of 48 mm x 20 mm, hypovascularised, located in the lower pole of the kidney with extension into the sinus. There were also enlarged lymph nodes laterally to aortic artery and between the aorta and the vena cava. A left radical nephrectomy with lymphadenectomy was performed. The histological examination with immuno-histo-chemical analysis revealed a renal medullary carcinoma T1N2R0 (TNM 2002). An adjuvant chemotherapy consisting of gemcitabine-cisplatin was administered. A regression of the residual lymph nodes was noticed after the six cycles of chemotherapy and the PET-Scan was negative. The patient underwent a second operation and the residual mass was excised. No tumor cell was found at the histological examination of the residual nodes. The patient had no clinical or radiological symptoms of progression eight months after the radical nephrectomy. We discuss the diagnostic criteria and analyse the therapeutic perspectives. Copyright 2009 Elsevier Masson SAS. All rights reserved.

YONDELIS-CAELYX FOR OVARIAN CANCER RELAPSED AFTER 6-12 MONTHS

Ann Oncol. 2010 Jul 19. [Epub ahead of print]
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, Lebedinsky C, Parekh T, Gómez J, Park YC, Alfaro V, Monk BJ.

Area of Gynecologic Oncology, Valencian Institute of Oncology, Valencia, Spain.
Abstract

BACKGROUND: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD) over PLD alone in relapsed ovarian cancer. The optimal management of patients with partially platinum-sensitive relapse [6-12 months platinum-free interval (PFI)] is unclear. PATIENTS AND METHODS: Within OVA-301, we therefore now report on the outcomes for the 214 cases in this subgroup. RESULTS: Trabectedin/PLD resulted in a 35% risk reduction of disease progression (DP) or death [hazard ratio (HR) = 0.65, 95% confidence interval (CI), 0.45-0.92; P = 0.0152; median progression-free survival (PFS) 7.4 versus 5.5 months], and a significant 41% decrease in the risk of death (HR = 0.59; 95% CI, 0.43-0.82; P = 0.0015; median survival 23.0 versus 17.1 months). The safety of trabectedin/PLD in this subset mimicked that of the overall population. Similar proportions of patients received subsequent therapy in each arm (76% versus 77%), although patients in the trabectedin/PLD arm had a slightly lower proportion of further platinum (49% versus 55%). Importantly, patients in the trabectedin/PLD arm survived significantly longer after subsequent platinum (HR = 0.63; P = 0.0357; median 13.3 versus 9.8 months). CONCLUSION: This hypothesis-generating analysis demonstrates that superior benefits with trabectedin/PLD in terms of PFS and survival in the overall population appear particularly enhanced in patients with partially sensitive disease (PFI 6-12 months).

MERCEL CELL CARCINOMA NATURAL HISTORY

From Journal of the National Cancer Institute
Abstract


Background Merkel cell carcinoma (MCC) is a rare skin cancer that was recently found to be associated with a polyomavirus and with immunosuppression, provoking new interest in its epidemiology. We conducted a nationwide study in Denmark to describe MCC incidence and mortality and the association between MCC and other cancers.
Methods We used data from Danish national health and population registers on MCC diagnoses, deaths, and population counts during the study period (1978–2006) to calculate MCC incidence rates, cumulative risks of MCC at age 100 years, and MCC mortality rates by tumor stage. We used Poisson regression to estimate the excess mortality rate ratio attributable to MCC and examined associations between MCC and other cancers diagnosed before and after the MCC diagnosis using standardized incidence rate ratios (SIRs). All statistical tests were two-sided.
Results Between January 1, 1978, and December 31, 2006, 185 persons were diagnosed with MCC in Denmark. MCC incidence between 1995 and 2006 was 2.2 cases per million person-years. In the first year after MCC diagnosis, 22% of persons with localized disease died compared with 54% of patients with nonlocalized disease; by 5 years after diagnosis, the proportions of MCC patients who had died increased to 55% and 84%, respectively. MCC incidence was statistically significantly increased more than 1 year after a diagnosis of squamous cell carcinoma of the skin (SIR = 14.6, 95% confidence interval [CI] = 8.4 to 25.6), basal cell carcinoma (SIR = 4.3, 95% CI = 2.7 to 6.6), malignant melanoma (SIR = 3.3, 95% CI = 1.1 to 10.3), chronic lymphocytic leukemia (SIR = 12.0, 95% CI = 3.8 to 37.8), Hodgkin lymphoma (SIR = 17.6, 95% CI = 2.5 to 126), and non-Hodgkin lymphoma (SIR = 5.6, 95% CI = 1.4 to 22.4). Squamous cell carcinoma (SIR = 12.1, 95% CI = 5.1 to 29.1) and chronic lymphocytic leukemia (SIR = 14.7, 95% CI = 3.7 to 58.8) occurred in statistically significant excess more than 1 year after MCC diagnosis.
Conclusions These results support the existence of shared risk factors for MCC and other cancers. Heightened awareness of the association between MCC and other cancers, particularly squamous cell carcinoma and chronic lymphocytic leukemia, may facilitate earlier clinical detection and treatment of MCC, thereby improving patient survival.

TROPONIN LEVELS AND TRASUZUMAB CARDIOTOXICITY

J Clin Oncol. 2010 Aug 2. [Epub ahead of print]
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation.
Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Lamantia G, Colombo N, Cortinovis S, Dessanai MA, Nolè F, Veglia F, Cipolla CM.

European Institute of Oncology and Centro Cardiologico Monzino, Istituto Di Ricovero e Cura a Carattere Scientifico, Milan, Italy.
Abstract

PURPOSE Treatment of breast cancer with trastuzumab is complicated by cardiotoxicity in up to 34% of the patients. In most patients, trastuzumab-induced cardiotoxicity (TIC) is reversible: left ventricular ejection fraction (LVEF) improves after trastuzumab withdrawal and with, or sometimes without, initiation of heart failure (HF) therapy. The reversibility of TIC, however, is not foreseeable, and identification of patients at risk and of those who will not recover from cardiac dysfunction is crucial. The usefulness of troponin I (TNI) in the identification of patients at risk for TIC and in the prediction of LVEF recovery has never been investigated. PATIENTS AND METHODS In total, 251 women were enrolled. TNI was measured before and after each trastuzumab cycle. LVEF was evaluated at baseline, every 3 months during trastuzumab therapy, and every 6 months afterward. In case of TIC, trastuzumab was discontinued, and HF treatment with enalapril and carvedilol was initiated. TIC was defined as LVEF decrease of > 10 units and below 50%. Recovery from TIC was defined as LVEF increase above 50%. Results TIC occurred in 42 patients (17%) and was more frequent in patients with TNI elevation (TNI+; 62% v 5%; P < .001). Twenty-five patients (60%) recovered from TIC. LVEF recovery occurred less frequently in TNI+ patients (35% v 100%; P < .001). At multivariate analysis, TNI+ was the only independent predictor of TIC (hazard ratio [HR], 22.9; 95% CI, 11.6 to 45.5; P < .001) and of lack of LVEF recovery (HR, 2.88; 95% CI,1.78 to 4.65; P < .001). CONCLUSION TNI+ identifies trastuzumab-treated patients who are at risk for cardiotoxicity and are unlikely to recover from cardiac dysfunction despite HF therapy.

A RARE SITE OF GERMINOMA

Neurol Med Chir (Tokyo). 2010;50(7):592-4.
Primary intramedullary spinal cord germinoma.
Kinoshita Y, Akatsuka K, Ohtake M, Kamitani H, Watanabe T.

Division of Neurosurgery, Faculty of Medicine, Institute of Neurological Sciences, Tottori University.
Abstract

A 21-year-old woman presented with an intramedullary spinal cord germinoma and a history of gait disturbance and elimination disorder. Magnetic resonance (MR) imaging demonstrated two isolated lesions, one located within the medulla between T9 and T11, and another at the cauda equina (L2 to L3 levels). After partial reduction of the intramedullary mass, histological findings revealed that the tumor was typical germinoma. Further MR imaging revealed no evidence of intracranial germinoma. Combined chemotherapy (carboplatin and etoposide) and whole spine radiation were performed. Follow-up MR imaging showed that the enhanced mass at the L2-L3 levels had disappeared. No recurrence of the tumor has been detected 3 years after the operation, and no dissemination into the cranial area was detected. Cisplatin and etoposide chemotherapy combined with radiotherapy is recommended for primary spinal germinoma, and is effective for inhibition of both tumor dissemination and recurrence.

LOW FERROPORTIN LEVELS INCREASE BREAST CANCER RECCURENCE RISK

August 4, 2010 — An iron-regulating protein known as ferroportin might play an important role in the clinical behavior of breast cancer, according to new biological experiments and analyses of clinical datasets.

The experiments and analyses are described in a paper published August 4 online in Science Translational Medicine.

Investigators from Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, found that low levels of ferroportin are associated with the most aggressive breast cancers.

In examining previously published datasets, the study authors also found that there is a metastasis-free survival advantage in breast cancer patients whose tumors have increased ferroportin gene expression.

Ferroportin, the only known protein to eliminate iron from cells, is "strikingly decreased in breast cancer tissue," say the authors, led by senior author Frank M. Torti, MD, MPH, director of the Comprehensive Cancer Center at Wake Forest.

They also note that "many cancers exhibit increased iron requirements" — probably because of the need for iron as a cofactor to sustain cancer cell growth and proliferation.

In short, the authors suggest that not enough ferroportin, with its ability to help eliminate iron from cells, contributes to more aggressive breast cancers and worse clinical outcomes.

The potential importance of iron in the proliferation of cancer is not news, say the authors. "Agents that deplete iron are currently under investigation as anticancer therapies," they point out.

However, what is news is that ferroportin seems to be, in the words of the authors, "a critical determinant of outcome in breast cancer."

Ferroportin might also be important in other tumor types, including hepatocellular carcinoma, prostate cancer, and leukemia, report the authors.

Biological Evidence

The Wake Forest investigators conducted a series of biological tests as a starting point in their evaluation of ferroportin.

First, they explored whether or not ferroportin is present in normal human breast epithelial cells, and if its levels are altered in breast cancer.

To do so, Dr. Torti and his team compared ferroportin protein levels in mammary epithelial cells with "variable malignant potential" from a woman with no breast cancer, from a woman with metastatic disease, and from a woman with inflammatory breast cancer.

The authors found that ferroportin levels were "reduced in all aggressive breast cancer cell lines when compared to their counterparts with little or no malignant potential."

Also, the researchers found that, in terms of the genetics of these cell lines, ferroportin mRNA levels were lower in the more malignant cells than in the nonmalignant cells. In other words, a stronger genetic expression of the protein was associated with healthier breast epithelial cells.

The researchers also noted, in other experiments, that a reduction of ferroportin in breast cancer cells was associated with an increase in the "labile iron pool" or metabolically available iron (which breast cancer cells can use for growth).

To determine whether ferroportin is decreased in human breast cancer tissue (as opposed to breast cancer cells that were examined earlier), the Wake Forest researchers performed immunohistochemical analysis.

A total of 154 samples of breast tissue from breast cancer patients and 6 samples from normal breasts were stained with antiferroportin antibody.

The authors report that 70% of normal samples received the highest staining intensity score, but that only 9% of the cancer samples received this score (P = .0015, Fisher's exact test); the result was "consistent with a reduction in ferroportin protein levels in human breast cancer tissue, as well as in breast cancer cell lines" say the authors.

The authors also used data from a cohort of 251 breast cancer patients to relate molecular subtypes — such as luminal A, luminal B, and basal — and their disease outcomes with the genetic expression of ferroportin in the patients. "Ferroportin was significantly differentially expressed among the subtypes, with lowest expression levels in the poor-prognosis subtypes," report the authors.

Does Ferroportin Expression Predict Clinical Outcome?

The preliminary evidence gathered by the researchers led to a pivotal question.

They explain in their paper that "the remarkably consistent decrease in ferroportin protein levels in malignant breast tissue and the association of decreased ferroportin gene expression with molecular subtypes of breast cancer with poor prognosis led us to ask whether ferroportin levels were related to breast cancer outcome."

So they performed an analysis using 4 large breast cancer datasets in the public domain that had both patient outcomes and microarray profiles.

"In all 4 studies, low ferroportin gene expression was associated with a statistically significant and clinically substantial reduction in metastasis-free survival," they report.

The "most dramatic effect" was seen in a Norwegian study in which the 8-year disease-free survival rates were separated by more than 30% — 77% for those with high ferroportin compared with 43% for those with low ferroportin (Proc Natl Acad Sci USA.2003;100:8418-8423).

What role ferroportin might have in elucidating the prognosis or even the therapy of breast cancer remains to be seen, conclude the authors. They point out that such matters are "best addressed in appropriately designed prospective trials." The authors did not indicate that any such trials are currently underway.

The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases.

Sci Transl Med. Published online August 4, 2010.

REVISED GUIDELINESS FOR THYROID CANCER TREATMENT

A revised version of the American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer provides an important review of current data on therapeutic modalities and offers improved clinical strategies for the optimal management of these thyroid pathologies.
Introduction

Only 3 years after the publication of its original guidelines,[1] the American Thyroid Association (ATA) has published a revised version of their recommendations in the November 2009 issue of Thyroid.[2] This new document represents an important upgrade and is the result of a careful and systematic review of the rapidly accumulating scientific evidence derived from high-quality studies. Although clinical practice guidelines can have their limitations, the publication of these clear and precise recommendations provides clinicians worldwide with the best available instrument for evidence-based management of thyroid disease.

The revised guidelines contain 124 evidence-rated recommendations, including an additional 38 guidelines compared with its predecessor,[1] which reflects the quantity as well as quality of research conducted in the area of thyroid disease. In addition, the task force responsible for reviewing the available evidence included experts from outside the US, as well as those who are involved in activities not exclusively related to thyroid disease. This approach has broadened the platform of expertise and improved the applicability of the guidelines worldwide.[3]

Two areas of the management of thyroid nodules have been extensively revised. First, we now have clear and specific recommendations on the size of thyroid nodules that require fine-needle aspiration biopsy (FNAB) in conjunction with their clinical and ultrasonographic features. Secondly, important updates are made on the interpretation of FNAB results, which in addition to the traditional four-category classification system (non-diagnostic, malignant, indeterminate and benign), now includes a new category (suspicious for malignancy), in keeping with the UK classification that is most commonly used in Europe.[4] Several important updates have also been provided with respect to the initial management of differentiated thyroid carcinomas. From a surgical perspective, a clear recommendation is made that for patients with thyroid cancers >1 cm in diameter, the initial procedure should be near-total or total thyroidectomy (recommendation 26). This recommendation should end the ongoing debate over thyroidectomy versus lobectomy for the management of thyroid carcinomas and bring the ATA's approach closer into consensus with current clinical practice in Europe.[5] The surgical approaches to locoregional lymph-node disease have been specifically reviewed, and a clear distinction is now made between prophylactic and therapeutic neck dissection. Therapeutic central and lateral compartment neck dissection is recommended for all patients with clinical involvement of central or lateral neck nodes (recommendations 27 and 28).[2] This procedure should improve locoregional control and decrease the need for repeated radioiodine (131I) administration, which could potentially improve survival.[5,6] Given the ongoing controversy and debate concerning prophylactic central compartment neck dissection,[7] the recommendations regarding this surgery are more cautious. Cure rates from differentiated thyroid cancer are high in most patients considered low-risk owing to the following characteristics: no local or distant metastases; complete macroscopic tumor dissection; no tumor invasion of locoregional structures; no aggressive histology and no 131I-uptake outside the thyroid on the first whole-body scan after treatment. One valid approach is to perform thyroidectomy only in these low-risk patients, with reoperation for recurrences in the small minority who eventually develop detectable lymph-node metastases—a strategy which avoids unnecessary morbidity in the majority of patients. One of the main advantages of prophylactic neck dissection, however, is to provide accurate staging of the tumor in order to refine the indications for and the doses of postoperative radioiodine.[6] The experience of the surgeon makes a notable difference in the risk–benefit analysis,[8] and the taskforce recommend that prophylactic neck dissection should be considered in patients with advanced tumors (stages T3 and T4)—an approach that might increase the risk of locoregional recurrence, but is on the whole a safer strategy in less-experienced hands than thyroidectomy alone.

The postoperative staging of thyroid cancers has been revised and a new three-level system that stratifies patients into low, intermediate or high risk categories is proposed. In comparison with the features of low-risk patients outlined above, those classified as intermediate-risk can have microscopic invasion of the tumor into perithyroidal soft tissues; cervical lymph node metastases; 131I-uptake outside the thyroid following thyroid remnant ablation or tumors with aggressive histology or vascular invasion. Patients are classified as high-risk when macroscopic tumor invasion, incomplete tumor resection or distant metastases are present. The authors of the revised guidelines acknowledge that, depending on the clinical course of the disease and the response to therapy, the risk of recurrence and mortality can change over time. The taskforce, therefore, suggests that ongoing reassessment of these risks is required, as new data are obtained during follow-up. The validity of this new prognostic stratification system will need to be evaluated in further prospective studies.

The evidence regarding 131I-ablation of tumor remnants has been meticulously and carefully reviewed. 131I should be administered to patients with primary tumors >4 cm in diameter when there is gross extra-thyroidal tumor extension and if distant metastases are present. This treatment is not recommended for tumors measuring <1 cm, even if they are multifocal. Selective use of 131I-remnant ablation is advised in patients with intermediate sized tumors (1–4 cm), in patients with lymph-node metastases and in patients with other high-risk features. With regards to radioiodine treatment of locoregional or distant metastases, the new edition of the guidelines makes no recommendation for or against dosimetry approaches, but greater emphasis has been placed on the side effects of 131I and the risk of exceeding the maximum tolerated radiation-absorbed dose when empiric fixed doses are used.

Some noteworthy updates have been established on the surveillance for thyroid cancer recurrence, and the importance of neck ultrasonography in this process has been stressed. Lymph nodes >5–8 cm at their smallest diameter that are suspicious for malignancy should be investigated with FNAB, and measurement of thyroglobulin levels in the needle washout fluid should be performed.

The usefulness of novel imaging techniques such as 2-deoxy-2-(18F)fluoro-D-glucose PET and of targeted therapies that use anti-angiogenic tyrosine kinase inhibitors have also been evaluated. After careful review of the evidence from phase II trials,[9,10] the guidelines recommend that patients with advanced disease, refractory to 131I-therapy, should be considered for treatment with tyrosine kinase inhibitors, either within or outside clinical trial settings. The concluding section of the guidelines is dedicated to future research and defines specific areas that require further exploration. These areas include the continued evaluation of novel therapies (angiogenesis inhibitors, immunomodulators and gene therapy approaches); the study of long-term risks of radioiodine; the improvement of risk stratification; the management of small cervical lymph-node metastases; and the need for a better understanding of persistently low but detectable levels of serum thyroglobulin.

The document produced by the ATA taskforce represents the most clear and precise set of guidelines available to clinicians who are committed to evidence-based clinical practice. Prospective studies urgently need to evaluate the validity of these new recommendations and define clinical outcomes in research that focus on critically controversial issues. Tailoring individual treatments to individual patients according to their risk profile through implementation of targeted therapies is the new paradigm shift and should be endorsed by thyroid associations throughout the world.
Sidebar
Practice Points

* Tumors >1 cm in diameter should initially be treated with near-total or total thyroidectomy
* Patients with involvement of central and lateral neck nodes should undergo therapeutic neck dissection
* Patients with advanced tumors (stages T3 and T4) should be treated with prophylactic neck dissection
* Ongoing stratification of patients into low, intermediate and high risk groups is required
* Ablative radioiodine therapy should be administered to patients with tumors >4 cm, extrathyroidal tumor invasion or distant metastases

Tyrosine kinase inhibitors should be considered for advanced disease refractory to radioiodine therapy

Τετάρτη 4 Αυγούστου 2010

NOTCH3 OVEREXPRESSION AND CARBOPLATIN RESISTANCE IN OVARIAN CANCER

Am J Pathol. 2010 Jul 29. [Epub ahead of print]
Notch3 Overexpression Is Related to the Recurrence of Ovarian Cancer and Confers Resistance to Carboplatin.
Park JT, Chen X, Tropè CG, Davidson B, Shih IM, Wang TL.

From the Departments of Pathology,* Pathobiology Graduate Program, and Oncology, Gynecology, and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland; the Section for Gynecologic Oncology, Division of Gynecology and Obstetrics, and the Division of Pathology, Norwegian Radium Hospital, Oslo University Hospital; and The Medical Faculty, University of Oslo, Oslo, Norway.
Abstract

Amplification of the Notch3 locus has been detected in ovarian high-grade serous carcinoma (HGSC), the most common and malignant type of ovarian cancer. We have previously demonstrated that ovarian cancer cells, which amplified and overexpressed Notch3, were dependent on Notch3 signaling for cellular survival and growth. In this study, we provide new evidence that Notch3 expression is associated with recurrent postchemotherapy HGSCs. Moreover, patients with recurrent HGSCs in effusion with high Notch3 expression had a significantly worse clinical outcome, including reduced overall survival and shortened progression-free survival than did patients with low Notch3 expressing HGSC. Ectopic expression of the Notch3 intracellular domain led to an increase in IC50 for carboplatin in an ovarian surface epithelial cell line and in a low-grade serous carcinoma cell line that expressed undetectable levels of Notch3. Interestingly, expression of the Notch3 intracellular domain increased expression of several genes associated with embryonic stem cells including Nanog, Oct4, Klf4, Rex1, Rif1, Sall4, and NAC1 as well as an ATP-dependent transporter gene, ABCB1. Knockdown of Notch3 resulted in sensitization to carboplatin in OVCAR3 that expresses abundant Notch3. Taken together, the above findings suggest that Notch3 pathway activation reprograms tumor cells to assume an array of embryonic stem cell markers and participates in development of chemoresistance in HGSC.

RECTAL RADIATION AFFECTS SEXUAL FUNCTION IN MEN

Their finding is drawn from patients in the previously reported Canadian MRC CR07/NCIC CTG C016 trial. In that study, men and women with operable rectal cancer had a 3-year local recurrence rate of 4.4% if they had short-course preoperative radiotherapy, compared to 10.6% if they had surgery first.

A secondary aim of the trial was to examine disease-related symptoms and adverse effects of treatment, to try to balance the advantages against any negative impact on quality of life.

In a June 28th online report in the Journal of Clinical Oncology, Lindsay C. Thompson of the Medical Research Council in London, UK, and colleagues note that 1208 patients in the trial (89% of the total cohort) completed the Medical Outcomes Study Short-Form 36-item (MOS SF-36) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal 38-item (EORTC QLQ-CR38) questionnaires.

There was a significant increase in male sexual dysfunction following surgery (p < 0.001) no matter the treatment arm. Starting at six months, however, men who had preoperative radiation therapy reported significantly greater dysfunction (p = 0.004), with the difference maintained for at least 2 years.

Very few women completed the sexual dysfunction questions, and so the researchers could not draw any firm conclusions about sexual dysfunction for that gender.

Patients in both treatment arms had similar decreases in physical function at three months. After that point, physical function returned to baseline in both groups. Treatment assignment seemed to have no major effect on general health or bowel function, but in an exploratory analysis more pre-op radiation patients had fecal incontinence at two years (53.2% vs 37.3%; p = 0.007).

The researchers hope their findings will help clinicians balance the benefits of preoperative radiation with its "detrimental toxicity" in their discussions with patients. They emphasize that preoperative radiation yielded fewer recurrences and that any modification of treatment shouldn't risk an increase.

"The challenges for the future are to further improve surgical techniques and to reliably identify low-risk patients who do not need preoperative radiotherapy," they conclude.

SOURCE: http://link.reuters.com/tek98m

Δευτέρα 2 Αυγούστου 2010

GENE GUIDED CHEMOTHERAPY NOT READY FOR PRIME TIME

July 27, 2010 — Three ongoing cancer trials funded by the National Cancer Institute have been suspended after the validity of the technology being used was called into question by a large group of US scientists.

Developed at Duke University, the technology now under question uses gene signatures to predict responses to chemotherapy. Two of the trials involve patients with non-small cell lung cancer (NCT00545948 and NCT00509366), and the third is in patients with breast cancer (NCT00636441).

The trials were suspended on July 22 and 23.

The move was made after a group of 31 scientists called on the National Cancer Institute to suspend the trials because of concerns over the prediction models that were being used. The models were developed on the basis of research reported by Anil Potti, MD, and Joseph Nevins, PhD, from Duke University, Durham, North Carolina, but the validity of those models has been questioned by peer-reviewed reanalyses of their work, the scientists note.

In a letter dated July 19 and addressed to the new National Cancer Institute director, Harold Varmus, MD, the group of researchers called for the trials to be suspended until a "fully independent review is conducted of both the clinical trials and of the evidence and predictive models being used to make cancer treatment decisions."

At the same time, one of the Duke scientists involved in developing the technology has been suspended from his place of work. Dr. Potti was placed on administration leave while the university investigates allegations that he had falsely claimed to be Rhodes scholar, according to a report in the New York Times.

In addition, one of the published papers that reported this technology has now come under scrutiny. The Lancet Oncology has issued an "expression of concern" over a paper published in the journal in 2007, which described the validation of gene signatures to predict the response of breast cancer to neoadjuvant chemotherapy (Lancet Oncol. 2007;8:1071-1078).

That research was praised by an independent expert contacted by Medscape Medical News at the time, as it showed for the first time that gene signatures could predict responses to individual chemotherapy regimens.

However, since its publication in 2007, the methodology used to generate the response predictions has been questioned by statisticians from the M.D. Anderson Cancer Center in Houston, Texas, the journal notes.

The Lancet Oncology was contacted by senior author Richard Iggo, PhD, from the Swiss Institute for Experimental Cancer Research in Epalinges, Switzerland, and first author Hervé Bonnefoi, MD, from the Institut Bergonié, University of Bordeaux, France. They "expressed grave concerns about the validity of their report in light of evolving events," and said they had repeatedly tried to contact their coauthors at Duke University (including Dr. Potti) without success.

The journal notes that the 15 European coauthors of the paper concur with the "expression of concern" notice that the journal has posted online and said that the 4 coauthors from Duke University have been contacted separately.

Controversy Surrounding Dr. Anil Potti and Duke University

The controversy surrounding Dr. Potti and his team's research at Duke University is outlined in exhaustive detail in a report published in the July 16 issue of The Cancer Letter. This publication found Dr. Potti's false claim of being Rhodes scholar in multiple grant applications submitted by him, and notes that the claim was also featured in a Duke newsletter in January 2007. However, this credential "disappeared" from Dr. Potti's biography later in 2007. The publication also found mentions of 2 other awards that it was unable to verify.

In addition to questions about Dr. Potti's credentials, The Cancer Letter notes that research coming out of his group has been "marred by corrections and even corrections of corrections," and points out that "errors in genomics research could have direct implications for patients."

Dr. Potti is considered to be a pioneer of personalized medicine because of his team's work on using gene signatures to predict responses to chemotherapy, and he has been featured in Duke University commercials aimed at the general public, the publication notes.

However, this work has been questioned by other scientists, it points out.

Two biostatisticians at the M.D. Anderson Cancer Center, Keith Baggerley, PhD, and Kevin Coombes, PhD, attempted to verify this work but found a series of errors, including mislabeling and mismatching of gene probe identifiers. They published their findings in November 2009 in the Annals of Applied Statistics (2009;3:1309-1334) and concluded: "Unfortunately, poor documentation can shift from an inconvenience to an active danger when it obscures not just methods but errors."

The biostaticians also suggested that the errors they found in the technology — which was being used in ongoing clinical trials to allocate patients to treatment group — may be putting patients at risk.

The Cancer Letter reports that as a result of that publication, Duke University temporarily suspended 3 clinical trials that were using gene signatures to assign patients to treatment — these are the same 3 trials that were suspended again a just few days ago.

However, even though Duke suspended those trials in October 2009, they were restarted again in January 2010 after an internal investigation by Duke's Institutional Review Board confirmed the research and concluded that this approach was "viable and likely to succeed."

When contacted by The Cancer Letter and shown documents obtained under the Freedom of Information Act, the 2 statisticians from M.D. Anderson who had questioned the technology said they were not satisfied by the internal review. "Duke's statement implies that other members of the scientific community should be able to replicate the reported results with the data available," they told the publication. "Having tried, we can confidently state that this is not yet true."

The letter to the National Cancer Institute from the group of 31 scientists, which comprises many professors of statistics and biostatistics from prestigious US universities, including Johns Hopkins, Harvard, and Princeton, refers both to the Annals of Applied Statistics paper and The Cancer Letter reports.

"It is absolutely premature to use these prediction models to influence the therapeutic options open to cancer patients," the letter says, as independent experts have been unable to substantiate the researchers' claims using the researchers' own data. If the data and analysis can be validated, then it would be appropriate to reinitiate the trials, but until then, suspension of the ongoing trials is necessary, "given the potential of patients being assigned to improper treatment arms...[and] the associated potential risk posed to these patients."

CANCER VACCINE-EFFECT ON SURVIVAL WITHOUT RESPONSES?

July 28, 2010 — Details of the pivotal clinical trial with the prostate cancer vaccine sipuleucel-T (Provenge; Dendreon), which showed an improvement in overall survival and led to the recent FDA approval of the product, have now been published in the New England Journal of Medicine.

Although the improvement in overall survival seen is "important," the lack of any measurable antitumor effect was "surprising," and the high cost of this new product is a "concern," comments Dan Longo, MD, in an accompanying editorial.

The pivotal trial, known as IMPACT, was sponsored by the manufacturer and headed by Philip Kantoff, MD, from the Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. It was conducted in 512 men with metastatic castration-resistant prostate cancer who were randomly assigned 2:1 to receive the vaccine or placebo.

The vaccine reduced the relative risk for death by 22% (hazard ratio, 0.78; P = .03), with overall survival improved to 25.8 months vs 21.7 months in the placebo group (4.1-month improvement).

This survival benefit is the best that has been reported in such patients to date.

Dr. Kantoff and colleagues note that in other recent phase 3 trials in metastatic castration-resistant prostate cancer, the median survival has ranged from 12.2 to 21.7 months, and the only approved therapy that has been shown to prolong survival, docetaxel, improved survival by 2 to 3 months compared with mitoxantrone and prednisone.

The reduction in the risk for death seen with the vaccine in these patients with metastatic disease "is an important step," comments editorialist Dr. Longo. However, he also raises a number of questions about some of the other findings in this study.

Lack of Antitumor Effect Is "Surprising"

"The improvement in survival came without evidence of a measurable antitumor effect," Dr. Longo points out. There was no significant effect on the time to tumor progression, and only 1 of 341 patients in the vaccine group showed a partial tumor response. In addition, only 3% of patients in the vaccine group showed a reduction in prostate specific antigen (PSA) of at least 50% on 2 visits at least 4 weeks apart.

This lack of antitumor is "surprising," Dr. Longo comments. "It is hard to understand how the natural history of a cancer can be affected without some apparent measurable change in the tumor, either evidence of tumor shrinkage or at least disease stabilisation reflected in a delay in tumor progression."

It also "raises the concern that the results could have been influenced by an unmeasured prognostic variable that was accidentally imbalanced in the study-group assignments," Dr. Longo writes.

However, this has been seen before, he points out. Another prostate cancer vaccine under development, PROSTVAC-VF (under development by Therion Biologics), also improved overall survival (by 8.5 months) without improving progression-free survival in a randomized phase 2 study (J Clin Oncol. 2010;28:1099-1105). This product is now in phase 3 clinical trials.

However, a third prostate cancer vaccine, known as GVAX (BioSante Pharmaceuticals), was unsuccessful in phase 3 testing, Dr. Longo notes.

High Cost is a Concern

"Another concern with sipuleucel-T treatment is the cost," Dr. Longo comments. The current cost of care for men with prostate cancer has been estimated at around $1800 per month. The vaccine costs $93,000, which works out at $23,000 per month of survival advantage.

"The high cost may affect use," Dr. Longo comments.

This has recently been discussed in a Medscape videoblog, entitled "Provenge Approved: Now How Much is a Life Worth?"

"It is also uncertain what role sipuleucel-T will ultimately play in the treatment of prostate cancer, given other promising treatments in development," Dr. Longo comments, specifically mentioning abiraterone (Cougar Biotechnology) and MDV3100 (Medivation). Both of these drugs are in phase 3 trials with survival as an end-point, as reported by Medscape Medical News.

The trial was supported by Dendreon.

N Engl J Med. 2010;265;411-422, 479-481.

IMAT MORE ACCURATE THAN IMRT

July 27, 2010 (Philadelphia, Pennsylvania) — Children with brain cancer who undergo chemotherapy may benefit from a technique known as intensity-modulated arc therapy (IMAT).

New research findings reported here at the American Association of Physicists in Medicine 52nd Annual Meeting by Chris Beltran, PhD, from St. Jude's Children's Research Hospital in Memphis, Tennessee, show that IMAT may effectively irradiate pediatric brain tumors while reducing exposure to surrounding tissue compared with the more conventional intensity-modulated radiation therapy (IMRT).

Dr. Beltran told Medscape Medical News, "We are always looking to minimize dosage to normal tissue. Any technology that can do that should be taken into account and evaluated." The study included 9 patients (mean age, 9.6 years) who were diagnosed with posterior fossa tumors and had been treated with IMRT within the past year.

"[The posterior fossa] is such a busy area, and it is very difficult to give an adequate dosage without hurting vital structures," Franklin Epstein, MD, chief of the Division of Neurosurgery at Audie L. Murphy Memorial Hospital in San Antonio, Texas, noted during an interview with Medscape Medical News in response to Dr. Beltran's findings. Dr. Epstein was not affiliated with the study.

Radiation therapy is designed to deliver full radiation to the target while minimizing exposure to the cochlea and other important surrounding tissues. However, Dr. Beltran pointed out that radiation of the whole brain and temporal lobes can result in hearing and cognitive damage. This led the investigators to test the efficacy of IMAT as an alternative treatment approach, subsequent to the initial course of IMRT.

The investigators replanned the children's therapy using 5 different approaches: 8 field non-coplanar IMRT, single coplanar IMAT, double coplanar IMAT, single non-coplanar IMAT, and double non-coplanar IMAT. Each of the therapy plans held the dose to 95% of the planning target volume constant.

The plans were then compared based on conformality index, monitor units, and dose to surrounding normal tissue.

In the case of double non-coplanar IMAT, the excess radiation dose (V50 and VD50) to both cochleae and temporal lobes was significantly decreased (P < .01) relative to IMRT. In contrast, the body V5 and monitor units were increased (P < .01). The double non-coplanar IMAT also resulted in improved conformality index (P = .05) relative to IMRT.

Dr. Beltran said the findings indicate that the double non-coplanar IMAT may be able to improve treatment of pediatric posterior fossa tumors compared with the standard non-coplanar IMRT.

The new IMAT technology appears to be able to better target the radiation and minimize adverse effects, Dr. Epstein observed. He said that the IMAT technique is "just a variation on a variation, and it could go right to clinical study."

The study did not receive commercial support. Dr. Beltran and Dr. Epstein have disclosed no relevant financial relationships.

American Association of Physicists in Medicine 52nd Annual Meeting: Abstract 12612. Presented July 18, 2010.

BLACK PATIENTS AND TRIPLE NEGATIVE BREAST CANCER

July 29, 2010 — A link between estrogen receptor–negative (ER-negative) and triple-negative breast cancer and African ancestry has been reported again in a new study published online July 22 in Cancer.

Researchers from the University of Michigan Comprehensive Cancer Center in Ann Arbor report that in their cohort, 82% of African women and 26% of American women of African ancestry had triple-negative disease. This was compared with 16% of white American patients with breast cancer.

As previously reported by Medscape Medical News, black women tend to be diagnosed at a younger age, present with a more advanced stage of disease at diagnosis, and have a higher risk for recurrence. They are also more likely to present with the triple-negative phenotype (negative for ER, progesterone receptor [PR], and human epidermal growth factor receptor 2 [HER2]), and are more likely to be ER-negative, which makes these women ineligible for hormone therapy.

Although the overall incidence of breast cancer among American black women is lower than in white women, breast cancer–related mortality is higher. However, even though multiple factors play a role in this disparity, studies have also shown that there may be biologic differences involved.

"While there are socioeconomic, cultural beliefs, and lifestyle factors involved, we believe that molecular differences also contribute to the more aggressive clinical features of breast tumors seen in these women," said Lori Field, PhD, the lead author of a study on genetic differences between black and white patients with breast cancer that was presented at the American Association for Cancer Research 2008 Annual Meeting. Dr. Field was with the Windber Research Institute, in Pennsylvania, when she presented her data.

Another recent study reported that triple-negative disease is 3-fold more common in black women compared with other races, regardless of age or body mass index. (Breast Cancer Res. 2009;11:R18).

Highest Prevalence of ER-Negative and Triple-Negative Disease

"A primary message of this work is that initiation of mammography screening at age 40 is particularly important for African-American women because of their increased risk for early-onset disease and for disease that is biologically more aggressive," said lead author Lisa A. Newman, MD, MPH, director of the Breast Care Center at the University of Michigan.

"Early detection of triple-negative breast tumors is extremely important," she told Medscape Medical News. "I personally advocate for mammography screening beginning at age 40 for white American women as well, in accord with American Cancer Society and American College of Surgeons recommendations."

In the latest study, Dr. Newman and colleagues compared disease patterns and selected clinicopathologic features among white and black American patients with breast cancer and African women with breast cancer who were treated at the Komfo Anokye Teaching Hospital in Kumasi, Ghana.

The study cohort included 1008 white American women, 581 black American women, and 75 Ghanaians, all of whom were diagnosed with invasive breast cancer. The mean age at the time of the diagnosis for Ghanaian women was 48 years, which was considerably lower than the median 60.7 years for black American women and 62.4 years for white American women (P = .0019).

The authors noted that the percentage of grade 3 lesions was also higher for the Ghanaian patients, as was the tumor size. Approximately three quarters (76%) of the Ghanaian patients were also diagnosed with ER-negative tumors compared with 36% for black American women and 22% for white American women. Ghanaian women also had the highest prevalence of triple-negative breast cancers observed in this group.

Within this cohort, 28 white American women (2.8%), 46 black American women (7.9%), and 57 Ghanaian women (76%) were diagnosed with poorly differentiated and stage III/IV breast cancer. An absence of expression of ERs was observed in 77.2% (n = 44) of Ghanaian women, 67.4% (n = 31) of black American women, and 50.0% (n = 14) of white American women (P = .043)

The authors also stratified the 2 cohorts of American women according to their menopausal status and then compared this status with the frequency of triple-negative breast cancers. Among premenopausal patients, black women had a higher prevalence of triple-negative breast cancer compared with white women, at 32.3% vs 25.2%. Both of these percentages were significantly lower than the rate observed among Ghanaian patients (82%), of whom the majority was younger than the commonly used menopausal surrogate cutpoint of 50 years. However, the authors point out that regardless of age, non-triple-negative tumors were rare among Ghanaian patients.

"Our study documented provocative patterns of increasing frequency for early onset/younger age at diagnosis, ER-negative/PR-negative, and triple-negative breast cancers in association with presumed increasing extent of African ancestry," the authors write. Further study of the breast cancer burden in African women could lead to identifying tumors or germline markers associated with high-risk disease, they suggest.

"Research programs that promote inclusion of African-American women onto clinical trials are extremely exciting," said Dr. Newman, pointing out that most National Cancer Institute–funded clinical trials' cooperative groups have Special Populations/Diversity Committees that specifically focus on enhanced accrual of diverse patient populations.

"I am currently working with my colleagues at the University of Michigan to develop clinical trials for breast cancer that we hope to activate in Ghana," she added.

Coauthor Celina G. Kleer, MD, was supported by a National Institutes of Health grant.

Cancer. Published online July 22, 2010.

COULD ALND BE AVOIDED IN T1cN0 ELDERLY PATIENTS WITH BREAST CANCER?

Ann Surg Oncol. 2010 Jul 23. [Epub ahead of print]
Axillary Dissection Versus No Axillary Dissection in Elderly Patients with Breast Cancer and No Palpable Axillary Nodes: Results After 15 Years of Follow-Up.
Martelli G, Miceli R, Daidone MG, Vetrella G, Cerrotta AM, Piromalli D, Agresti R.

Breast Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, Milan, Italy, gabriele.martelli@istitutotumori.mi.it.
Abstract

OBJECTIVE: To assess the long-term safety of no axillary clearance in elderly patients with breast cancer and nonpalpable axillary nodes. BACKGROUND: Lymph node evaluation in elderly patients with early breast cancer and clinically negative axillary nodes is controversial. Our randomized trial with 5-year follow-up showed no breast cancer mortality advantage for axillary clearance compared with observation in older patients with T1N0 disease. METHODS: We further investigated axillary treatment in a retrospective analysis of 671 consecutive patients, aged >/=70 years, with operable breast cancer and a clinically clear axilla, treated between 1987 and 1992; 172 received and 499 did not receive axillary dissection; 20 mg/day tamoxifen was prescribed for at least 2 years. We used multivariable analysis to take account of the lack of randomization. RESULTS: After median follow-up of 15 years (interquartile range 14-17 years) there was no significant difference in breast cancer mortality between the axillary and no axillary clearance groups. Crude cumulative 15-year incidence of axillary disease in the no axillary dissection group was low: 5.8% overall and 3.7% for pT1 patients. CONCLUSIONS: Elderly patients with early breast cancer and clinically negative nodes did not benefit in terms of breast cancer mortality from immediate axillary dissection in this nonrandomized study. Sentinel node biopsy could also be foregone due to the very low cumulative incidence of axillary disease in this age group. Axillary dissection should be restricted to the small number of patients who later develop overt axillary disease.

DCIS-WHEN CANCER IS NOT CANCER

July 29, 2010 — Recent media reports of potential misdiagnosis and overtreatment of early-stage breast cancer may be frightening women away from recommended screening for breast cancer, according to a joint news release from Susan G. Komen for the Cure and the College of American Pathologists.

Rather than forgo screening because of fears of being misdiagnosed and receiving unnecessary therapy, women should know what questions to ask and be confident about weighing their options, the release emphasizes.

The joint statement was released primarily in response to a recent article in the New York Times, which described the disturbing case history of a women misdiagnosed with ductal carcinoma in situ (DCIS). The patient had a "golf-ball sized" section of her breast removed, underwent radiation and chemotherapy, and then was told a year later that she never had cancer.

According to the article, the patient stated that the fear was the worst of all. "Psychologically, it's horrible.... I never should have had to go through what I did," she said.

The New York Times article highlights an issue that is a subject of much discussion among oncologists. Advances in mammography and other imaging technology during the last 3 decades have allowed visualization of extremely small lesions, according to the article. It may be particularly challenging for pathologists to distinguish the difference between some benign lesions and early-stage breast cancer.

Flip of a Coin

The diagnosis of DCIS "is a 30-year history of confusion, differences of opinion and under- and overtreatment," said Shahla Masood, MD, the head of pathology at the University of Florida College of Medicine in Jacksonville, in the New York Times article. "There are studies that show that diagnosing these borderline breast lesions occasionally comes down to the flip of a coin."

In response to concerns about the accuracy of breast pathology, the College of American Pathologists has announced that it will begin a voluntary certification program for pathologists who read breast samples. Among the requirements is that pathologists must read 250 breast cases a year. In addition, in a response to concerns that approximately 17% of DCIS cases identified by needle biopsy may be misdiagnosed, a new study supported by the federal government will be conducted to examine the variations in breast pathology.

However, as noted in the New York Times article, there are currently no mandated diagnostic standards or requirements for pathologists who evaluate breast tissue samples. This means that diagnostic accuracy can vary among facilities, depending on the individual expertise of the pathologists.

Is DCIS Really a Cancer?

As previously reported by Medscape Medical News, some experts believe that the term "carcinoma" in the phrase "ductal carcinoma in situ" is misleading and troubling and ought to be dropped, or at least that its elimination should be considered. In fact, in some cases experts suggest that DCIS is a possible candidate for management by active surveillance — a treatment strategy of growing importance in prostate cancer in which low-risk patients are monitored but do not receive active treatment unless they progress to a higher risk.

However, others disagree. "Although active surveillance is a step that can mitigate the harms of treatment, we doubt that it will mitigate the effects of uncertainty and anxiety," H. Gilbert Welch, MD, Steven Woloshin, MD, and Lisa M. Schwartz, MD, from the Department of Veterans Affairs and Dartmouth Medical School, New Hampshire, comment in an editorial (J Natl Cancer Inst. 2008;100:228-229).

"To do this, we must go back a step and question the value of making the diagnosis in the first place," they write.

The editorialists note that there "is a sea of uncertainty surrounding DCIS. Some lesions will progress to cancer, others will not. Some women with DCIS will develop cancer elsewhere in their breasts, whereas others will not. And we're not sure what the chances are."

In her Medscape videoblog, Kathy Miller, MD, notes that there has been a "long understanding that we overtreat patients DCIS," and that it is a "disease that we rarely had to deal with in the days before mammograms."

"But with mammograms, about a third of patients diagnosed with breast cancer are diagnosed with DCIS and they are virtually all treated," said Dr. Miller, an associate professor of medicine at Indiana University School of Medicine, Indianapolis. "It's almost as frightening, if not as frightening, as for those patients diagnosed with invasive disease."

Dr. Miller noted that with advancing technology, there will come a time when patients with DCIS can be better defined as to whether or not their disease is likely to progress. Those patients will likely need treatment, whereas others can simply be monitored.

"But we can't do that now," she pointed out. "If you have carcinoma in the name, that makes doing nothing scary for patients, scary for doctors, and untenable for everyone."

Although simply changing the name will not remove the fear, changing the name could start to change the mindset, she added. "[It] could make it easier, could make it possible to study which patients need treatment and which patients don't. And [it] could go a long way to moving how we think about the disease in a way that could be very helpful."

GENE TRANSFER FOR B-THALASSEMIA

July 26, 2010 — Preclinical trials of a genetic treatment for β-thalassemia have demonstrated the potential to successfully correct the genetic error underlying this disease. The normal β-globin gene was inserted into patients' hemopoietic cells from bone marrow aspirates, increasing β-globin production to levels typically found in carriers of the mutation.

The study, led by an Italian group based at the San Raffaele Scientific Institute in Milan, was reported online July 21 in EMBO Molecular Medicine.

β-thalassemia is a genetic disease caused by the absent or reduced ability to produce β-globin — a protein that constitutes 2 of the 4 protein chains in normal hemoglobin. If 1 of a person's 2 genes is mutated, the individual is a carrier, with only mild anemia. However, patients with 2 mutant genes show symptoms of severe anemia including pallor; dark urine; slow growth; enlargement of the liver, heart, and spleen; and bone problems. The disease occurs primarily among individuals of Mediterranean, African, or Asian heritage.

Standard treatment involves transfusions as often as every 2 to 4 weeks, introducing additional problems such as infection and iron overload, with complications involving heart and kidney damage.

"Treatments are limited to lifelong regular blood transfusions, and iron chelation to prevent fatal iron overload," said senior author Giuliana Ferrari, PhD, from the San Raffaele Telethon Institute for Gene Therapy, in a press release. "The alternative is bone marrow transplantation, an option open to less than 25% of patients."

"Iron overload is due to [the] hemolytic process, higher absorption, and to transfusions," added Dr. Ferrari in an email to Medscape Medical News.

Participants in the study were 44 patients with β-thalassemia major or intermedia, from 2 to 15 years old, of varied Mediterranean origins (eg, Palestinian, Iraqi Kurd, Lebanese, Syrian, and others), who represented a variety of mutations in the β-globin gene. All were enrolled in bone marrow transplant programs.

Investigators obtained bone marrow samples from the patients as a source of CD34+ cells (hemopoietic cells). As the report explains: "Correction of β-thalassemia by gene therapy requires gene transfer in stem/progenitor cells and high levels of β-globin gene expression in the differentiated erythroid progeny." The CD34+cells were transduced with a lentiviral vector, LV GLOBE, engineered to contain the normal β-globin gene, and were then cultured for 14 days.

As part of this procedure, the CD34+ progenitor cells are also treated with cytokines "to maximize the efficiency of gene transfer in CD34 cells, since the cells are committed to cell cycle," Dr. Ferrari told Medscape Medical News. "In this condition the vector works best, rather than in really quiescent cells."

Gene transfer efficiency ranged from 37% to 95%, with an average of 65%. Analysis of transduction efficiency in cultured cells found that the proportion of cells from patients with β-thalassemia producing normal hemoglobin was comparable with that of normal individuals (44.6% ± 6.7% compared with 53.8% ± 7.2%). Transduced cells from patients with β-thalassemia who had produced low levels of β-globin also significantly increased their production of normal hemoglobin (P < .05).

In cells from 2 control patients, the ratio of β-globin/α-globin synthesis was .97 and .79. In transduced cells that had completely lacked β-globin production, the ratio improved to .30, and cells that had previously exhibited low β-globin production achieved a ratio of .35.

The study also investigated the tendency for the viral vectors to integrate the normal β-globin gene at a disruptive location, especially at loci involving protooncogenes. In the 4 patients with β-thalassemia who were analyzed, the vectors integrated at 403 unique sites. There was a low tendency (6.4% of the time) to "integrate at recurrent sites (hot spots)" in the genome. Although 3 hot spots were in cancer-related genes, in general the vector exhibited "no tendency...to integrate into protooncogenes."

A "Close Up" article in the same issue of Molecular Medicine drew 3 messages from the study. First, the manipulations involved in transduction with the viral vector did not impair hemopoietic cells' function or general gene expression. Second, at low copy number (about 84% of the hemopoietic cell colonies in culture contained 1 to 4 copies of the vector), the vector could correct β-globin expression, leading to red blood cell formation in offspring of the transduced cells. Finally, the LV GLOBE vector behaves like other lentiviral vectors, with no bias toward integrating in oncogenes.

"This work represents the kind of translational studies that are required to move human investigations forward but are often very difficult to fund and publish," wrote coauthor David A Williams, MD, chief of the Division of Hematology/Oncology, and director of translational research, Children's Hospital Boston, Massachusetts.

Asked about his expectations for use of genetic therapies, Dr. Williams told Medscape Medical News via email: "There will be applications more widely in monogenic diseases in hematology [and] immune diseases, but also in other organ systems (eg, the eye studies). There will be applications in nonmonogenic diseases such as autoimmune or rheumatologic disease and cancer," said Dr. Williams, and "potentially in [central nervous system] degenerative processes."

For β-thalassemia, Dr. Williams was cautiously optimistic about gene therapy replacing bone marrow transplants: "Difficult to say at this point, but if gene therapy were to uniformly work and not have excessive toxicities, it might well be the preferred therapy. Its advantage is that it eliminates risk of [graft-versus-host disease] and eliminates need to find a donor. However," he concluded, "we are still away from this being reality."

"Allogeneic transplantation is the cure of choice in case of [a] compatible donor," agreed Dr. Ferrari. "Gene therapy is still a trial whose benefit needs to be proven."

The authors of the study and of the Close Up article have disclosed no relevant financial relationships.

EMBO Mol Med. Published online July 21, 2010.

MOST MEN WITH LOW RISK PROSTATE CANCER GET HIGH RISK TREATMENT

July 26, 2010 — A majority of men with newly diagnosed low-risk prostate cancer choose to undergo aggressive local intervention with either radical prostatectomy or radiation therapy, despite the high risk for complications and adverse effects and the availability of active surveillance as an alternative.

These conclusions, drawn from a study published in the July 26 issue of the Archives of Internal Medicine, once again illustrate the problems of overtreatment of prostate cancer, say experts contacted by Medscape Medical News.

In the study, Grace L. Lu-Yao, PhD, and colleagues from the Cancer Institute of New Jersey, in New Brunswick, analyzed data from the Surveillance, Epidemiology, and End Results database and found 123,934 men with prostate cancers that were newly diagnosed between 2004 and 2006.

The researchers found that 14% of the men had prostate-specific antigen levels lower than 4.0 ng/mL — the widely accepted threshold for recommending biopsy. Of this group, 54% had low-risk disease features, including disease confined within one half of 1 lobe of the prostate (stage T2a or less), Gleason score of 6 or less, and a PSA of 10 ng/mL or less.

Yet more than three fourths of all patients with PSAs lower than 4.0 ng/mL elected to undergo radical prostatectomy or radiation therapy. The team found that 44% of men with PSAs lower than 4.0 ng/mL underwent radical prostatectomy, and 33% had radiation.

"Our study found that aggressive local therapy was provided to most patients diagnosed as having prostate cancer," Dr. Lu-Yao and colleagues write.

"These results underscore the fact that PSA level, the current biomarker, is not a sufficient basis for treatment decisions. Without the ability to distinguish indolent from aggressive cancers, lowering the biopsy threshold might increase the risk of overdiagnosis and overtreatment," the investigators write.

Men with cancers detected by screening had a significantly lower risk of having high-grade disease compared with men with cancers detected by other means (odds ratio [OR] for screening, 0.67; 95% confidence interval [CI], 0.60 - 0.76), but the screen-detected cancers in men with PSAs lower than 4 were significantly more likely to be treated with either surgery (OR, 1.49; 95% CI, 1.38 - 1.62) or radiation (OR, 1.39; 95% CI, 1.30 - 1.49).

The same group of researchers has previously reported that conservative management of prostate cancer diagnosed in the age of PSA — from the 1990s on — had better outcomes than conservative management of disease diagnosed in the 2 previous decades, possibly because of "additional lead time, overdiagnosis related to PSA testing, grade migration, or advances in medical care" (JAMA. 2009;302(11):1202-1209).

Informed Discussions Best Antidote to Overdiagnosis, Overtreatment

An informed discussion between physician and patient is the best means for ensuring that patients get the appropriate treatment for their disease stage and grade, says coauthor Robert S. DiPaola, MD, from the Cancer Institute of New Jersey, and associate dean for oncology programs and professor of medicine at University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School in Piscataway, in an interview with Medscape Medical News.

"It's not because we would say there's some cutoff here, because there are men diagnosed with prostate cancer who have PSAs less than 2 or 2.5 [ng/mL]. I think it really needs to be an informed discussion over biopsy vs no biopsy, based on a number of different parameters, including exam, prostate size, perhaps ultrasound, PSA velocity, and PSA level related to age," he said.

Armed with that information, the clinician can then discuss with the patient his prognosis and his options for therapy.

"For example: A man 75 [years old] or so with an average, say, stage T1c tumor would have about a 10% chance of dying from prostate cancer in his lifetime, and based on that they can discuss whether that warrants for him radical prostatectomy or radiation. Obviously, for younger men we tend to err on the side of local therapy," Dr. DiPaola says.

He cautions, however, that there are as yet no reliable means for accurately determining risks for individual patients, which is why many men who might otherwise die from other causes still undergo aggressive therapies.

"A Frightening Piece of Information"

A proponent of active surveillance of low-risk prostate cancer patients tells Medscape Medical News that overdiagnosis and overtreatment of prostate cancer is a major problem for urologists, oncologists, and patients today.

"I think if you look around the country at what's happening with prostate cancer management in general, young men have surgery, and they're overwhelmingly more likely to have surgery than radiation treatment, and what we're trying to do is find those who don't need either," says Donald S. Kaufman, MD, director of the Claire and John Bertucci Center for Genitourinary Cancers at Massachusetts General Hospital in Boston.

"The business of taking people who are younger with PSAs that are lower and have biopsies that show cancer and then have surgery is actually a piece of frightening information which we're all aware of, and this paper brings it out very nicely," he says.

Lowering guideline-recommended PSA cutoffs to 2.5 or 2.0 ng/mL, as has been proposed in recent years, would make a bad situation even worse, and could result in an additional 400,000 cases of prostate cancer, "and God knows who's going to take care of them, except that if they did nothing it would be better," Dr. Kaufman adds.

Philip Kantoff, MD, director of the genitourinary cancer program at the Dana-Farber Cancer Institute in Boston, agrees.

"There is a changing tide in the field through the recognition of a variety of studies, including this one, that a substantial number of people, particularly in the good-risk category with good-risk features, don't require treatment but have been getting treatment, and we need to improve our ability to identify these people and to figure out reasonable strategies for following them," Dr. Kantoff tells Medscape Medical News.

Not "Watchful Waiting" but "Active Surveillance"

Although many men balk at the idea of waiting around for something to happen — a common perception of traditional "watchful waiting" — active surveillance, with yearly or biannual biopsies, digital rectal exams, and PSA testing every 3 to 6 months, can be an effective alternative for many men with low-risk prostate cancers, say Richard M. Hoffman, MD, MPH, from the New Mexico VA Health Care System and University of New Mexico School of Medicine in Albuquerque, and Steven B. Zeliadt, PhD, from the VA Puget Sound Health Care System and University of Washington in Seattle, in an accompanying editorial.

"Active surveillance is considered an acceptable alternative for men with cancers at low risk for progression as defined by a PSA level of 10 ng/mL or lower, a Gleason score of 6 or lower, and a clinical stage of T1c or T2a," they write. "For men who select active surveillance, the choice to undergo deferred treatment remains available and can be based on evidence of disease progression (rising PSA level, increasing Gleason score, and/or an abnormal [digital rectal exam] finding) and/or patient preference."

Active surveillance should not be restricted to men 65 years and older, because many younger men will also have biopsy-proven cancer that would otherwise not cause them problems during their lives, Dr. Kaufman says.

"I see so many highly intelligent young men who come in having had a biopsy which shows a minimal amount of Gleason 6 cancer, and they'll say 'I have cancer and I want it out — I don't want to hear about it and I don't want to talk about it,' " Dr. Kaufman says. "A lot of those patients listen to us and end up having active surveillance."

His center recommends active surveillance in about 25% to 30% of men with newly diagnosed prostate cancer, and "if you follow a precise active surveillance program, as we have our patients do, nobody gets into trouble," he says.

The study was sponsored by grants from the National Cancer Institute, Cancer Institute of New Jersey, and Robert Wood Johnson Foundation. The authors, editorialists, Dr. Kaufman, and Dr. Kantoff have disclosed no relevant financial relationships.

Arch Intern Med. 2010;170:1256-1261.

PREDICTIVE TEST FOR CML RESISTANCE TO IMATINIB

July 29, 2010 — A highly sensitive and specific test in the works may be able to predict which patients with chronic myeloid leukemia (CML) will develop resistance to imatinib (Gleevec; Novartis) and may also predict responses to alternative agents, the test's developers claim.

The test, which is still under development, uses a biosensor to characterize the activity of the BCR-ABL kinase, the target of imatinib, in cells from patients with CML. It works with relatively few cells and can spot early signs of drug resistance by detecting resistant cell populations constituting less than 1% of a sample, the investigators write in the August 1 issue of Clinical Cancer Research.

The test uses fluorescence resonance energy transfer (FRET), a technique for measuring the interaction of 2 proteins, write Yusuke Ohba, MD, PhD, associate professor at the Hokkaido University Graduate School of Medicine in Sapporo, Japan, and colleagues.

"Using this test, we are now able to identify and predict the most suitable treatment option for individual [patients with CML]," Dr. Ohba says in a press release. "This technique is both sensitive and practical to use; it is especially useful for patients who are in relapse, a case in which the clinician's important decision regarding the next step in treatment must be made quickly and accurately."

The study has important implications for clinical practice beyond CML, write Shaoying Lu, PhD, and Yingxiao Wang, PhD, from the University of Illinois Urbana-Champaign, in an accompanying editorial.

"[T]he authors showed that the FRET biosensor in combination with flow cytometry can be used to detect a small percentage of drug-resistant cancer cells mixed in a large cell population. This finding is exciting because these drug-resistant cells may likely constitute the main reason for CML relapse and therapeutic failure," they write.

"Therefore, the FRET biosensor developed here can provide a powerful tool to assess the biopsy samples from a particular patient and to predict the future probability of his or her resistance to specific drugs. This tool should provide invaluable information for clinicians and physicians to identify and design alternative therapeutic approaches with better efficiency and higher chances of success," they add.

Protein Sandwich With Pickles

Dr. Ohba and colleagues dubbed their test "Pickles" (for phosphorylation indicator of CrkL en substrate). They created it by sandwiching the adapter protein CrkL, which is known to bind to BCR-ABL, between 2 layers of fluorescent proteins. They saw a roughly 80% increase in FRET efficiency — a measure of fluorescence intensity indicative of activity in the presence of BCR-ABL.

After tweaking the biosensor for optimal response, they tested its ability to identify drug-resistant cells within cultures and to determine which tyrosine kinase inhibitor would be most effective against a given mutation. For example, they showed that small populations of cells resistant to imatinib and to nilotinib (Tasigna; Novartis) were sensitive to dasatinib (Sprycel; Bristol-Myers Squibb).

They then tested the technique for its ability to evaluate drug efficacy in cells obtained from 11 patients with CML and found that the test results both accorded with current patient status and were predictive of future outcomes.

"In view of the results we are obtaining, we feel confident that following our study using a large patient cohort, this Pickles-based method will be used successfully to provide reliable information about drug sensitivity in CML, both at the time of initial diagnosis and during the course of the disease, as well as to predict potential future recrudescence during/after imatinib therapy," the investigators write.

The study was supported by grants from the Japanese government, Japan Society for the Promotion of Science, Japan Health Sciences Foundation, and Yasuda Medical Foundation. The investigators and the editorialists disclosed no potential conflicts of interest.

Clin Cancer Res. 2010:16;3964-3975, 3822-3824.

PROGNOSIS FRO MPNST SARCOMA

Ann Oncol. 2010 Jul 23. [Epub ahead of print]
First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study.
Kroep JR, Ouali M, Gelderblom H, Le Cesne A, Dekker TJ, Van Glabbeke M, Hogendoorn PC, Hohenberger P.

Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Abstract

BACKGROUND: The role of chemotherapy in advanced malignant peripheral nerve sheath tumor (MPNST) is unclear. PATIENTS AND METHODS: Chemotherapy-naive soft tissue sarcomas (STS) patients treated on 12 pooled nonrandomized and randomized European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials were retrospectively analyzed. Clinical outcomes, overall survival, progression-free survival (PFS) and response were determined for MPNST and other STS histotypes and compared. Additionally, prognostic factors within the MPNST population were defined. Studied cofactors were demographics, sarcoma history, disease extent and chemotherapy regimen. RESULTS: After a median follow-up of 4.1 years, 175 MPNST out of 2675 eligible STS patients were analyzed. Outcome was similar for MPNST versus other STS histotypes, with a response rate, median PFS and overall survival of 21% versus 22%, 17 versus 16 weeks and 48 versus 51 weeks, respectively. Performance status was an independent prognostic factor for overall survival. Chemotherapy regimen was an independent prognostic factor for response (P < 0.0001) and PFS (P = 0.009). Compared with standard first-line doxorubicin, the doxorubicin-ifosfamide regimen had the best response, whereas ifosfamide had the worst prognosis. CONCLUSION: This series indicates the role of chemotherapy in treatment of advanced MPNST. This first comparison showed similar outcomes for MPNST and other STS histotypes. The apparent superiority of the doxorubicin-ifosfamide regimen justifies further investigations of this combination in randomized trials.

FISH FOR ABNORMAL CIRCULATING CELLS IN NSCLC PATIENTS

July 28, 2010 — A simple blood test in development may identify patients with non-small cell lung cancer (NSCLC) who are at high risk for metastasis, say authors of a pilot study reported online July 22 in Clinical Cancer Research.

Welcoming the news, several lung cancer experts said that it would be very useful to have a noninvasive test to monitor disease, but cautioned that this test is not ready yet for clinical use.

The test uses fluorescent in situ hybridization, or FISH, to spotlight abnormal circulating cells in chromosomal sites known to harbor genetic abnormalities in patients with NSCLC.

Looking at blood samples from 59 patients with stages I to IV NSCLC and 24 high-risk control patients (participants in a lung cancer screening program), the test identified significantly higher numbers of cytogenetically abnormal cells (CACs) in patients with cancer vs control patients, with the numbers rising in proportion with disease stage, write Ruth L. Katz, MD, professor of pathology at the University of Texas M D. Anderson Cancer Center, in Houston, and colleagues.

"We showed that the numbers of CACs were much higher in patients with advanced lung cancer, such as stage IV with cancer spread throughout the body, compared to patients with stage IA, small cancers confined to the lung," said Dr. Katz in a media briefing.

When the team looked at 12 DNA biomarker abnormalities in peripheral blood and tumor tissue from 21 patients who underwent surgical resection of their lung tumors, "we showed that there was generally an excellent correlation between most of the biomarkers in the CACs in the blood and in the tumor cells. We also showed that the CACs in general had few genetic abnormalities compared to most tumor cells. However, there was always a cell population in the tumor that matched the genetic abnormalities seen in the circulating CACs," she added.

Noninvasive Test Would Be Useful

At the same media briefing, organized by the American Association for Cancer Research, several lung cancer experts who were not involved in the study commented on the findings.

This test appears to be more accurate than current methods for isolating circulating tumor cells using antibody capture of circulating epithelial cells, said Fred R. Hirsch, MD, PhD, professor of medicine and pathology at the University of Colorado Cancer Center in Aurora. If it is validated in larger studies, it could help with early detection of primary disease and relapse, and also with treatment monitoring, he added.

"In terms of early diagnosis of lung cancer, and also monitoring recurrence and monitoring effect of therapy, we use most often invasive procedures, which might be more traumatic for the patient. If it is possible to use circulating blood cells, it would be much easier to get access to it, and much more comfortable for the patient, and I think those are 2 important factors here," Dr. Hirsch commented at the briefing.

Not Ready for Prime Time

"The ability to use a blood sample as a means by which to follow patients getting therapy for whatever malignancies is incredibly important and has a huge potential advantage for our patients," commented Minetta Liu, MD, director of the Translational Breast Cancer Research Program at the Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC.

Dr. Liu cautioned, however, that the study only involved 59 patients, and that a great deal more work needs to be done before the test is ready for the clinic.

"Although there is a lot excitement about the work that was presented here by Dr. Katz, we're not sure that this should be used in any way, shape, or form yet in terms of guiding what we should be doing with our patients," she said, a remark echoed by Roy Herbst, MD, PhD, chief of the section of thoracic medical oncology at the University of Texas M.D. Anderson Cancer Center, and a senior editor of Clinical Cancer Research.

Are They Circulating Tumor Cells?

Dr. Katz and colleagues are reluctant at this stage to state unequivocally that the CACs they identified are circulating tumor cells, but the evidence points in that direction based on several factors, they say.

For one, 8 of the DNA biomarkers in the peripheral blood mononuclear cells tested correlated with those in resected lung tumors. In addition, for each of the 12 biomarkers tested, mean percentages of genetically altered cells correlated with the stage of NSCLC, with the highest levels occurring in samples from patients with stage III or IV disease; control patients had significantly fewer abnormal cells than the patients with cancer.

The investigators plan to develop the antigen-independent test for clinical use.

"We are trying to work out exactly which panel of biomarkers we should be using," Dr. Katz said. "In this particular paper we used 12 biomarkers, but it was really redundant, because all of the biomarkers showed very similar things, so we want to use biomarkers that are very easy to quantitate."

If it proves its mettle in further studies, the test could be rolled out across the United States, because it uses a platform currently employed in laboratories for examining cytogenetic abnormalities in urine, Dr. Katz added.

The study was supported by the National Cancer Institute and by AstraZeneca. Dr. Katz has disclosed receiving a commercial research grant from AstraZeneca and has a patent pending.

Clin Cancer Res. Published online July 22, 2010.

BREAST DENSITY AND REDUCED MAMOGRAM SENSITIVITY

July 29, 2010 — Poorer outcomes from conventional mammography screening of women in their 40s are primarily a result of sensitivity limits of the technology, rather than tumor biology, suggest authors of a study published online July 27 in the Journal of the National Cancer Institute.

Nearly 80% of the difference between outcomes in younger vs older women is accounted for by the inability of mammography to detect small tumors in the breast tissue of younger women, and about 20% is accounted for by faster tumor-volume doubling times, report Sylvia K. Plevritis, PhD, and colleagues from the Department of Radiology at Stanford University School of Medicine in California.

"Our results underscore the importance of continued efforts to improve technologies for early detection of breast cancer in younger women, particularly in women with dense breast tissue," they write.

Both digital mammography and ultrasound have been shown in recent trials to be more sensitive for detecting breast cancer in women with dense tissues and should be considered for improving the sensitivity of screening in younger women, the authors note.

A mammography expert who was not involved in the study told Medscape Medical News that the results are in keeping with current understanding of the limits of conventional mammography in women younger than a certain age, and point to the need for better screening methods in this population.

"If you're talking about tumor detectability at a point in time, it really doesn't matter whether the thing is doubling fast or slow if you can't see it, so more important, I think, is the density and the difficulty of detecting a tumor," said Avice O'Connell, MD, head of women's imaging at the University of Rochester Medical Center and James P. Wilmot Cancer Center in Rochester, New York.

Dr. O'Connell notes that Connecticut now requires that all women of any age who undergo mammography in that state be informed of breast density findings. Women who are deemed to have breast density of grade 3 (heterogeneous, with dense tissue making up more than 50% of the breast) or grade 4 (extremely dense breast with very little fat) receive a letter stating that they might benefit from supplementary screening tests, such as breast ultrasound, magnetic resonance imaging, or both, depending on individual risk factors.

"We can't make their breasts less dense, so we just have to work out what these women should have," Dr. O'Connell said. "If money were no object, every woman with breast density above 50% should have another test — whole breast ultrasound if you can find somebody to do it, [magnetic resonance imaging] if you can find somebody to pay for it, or one of the newer technologies coming up, molecular imaging, which is even more expensive."

Computer Simulation Model

In the new study, the Stanford investigators arrived at their conclusions by creating a computer simulation model of breast cancer screening by age. The model estimated the median tumor size detectable on a mammogram and the mean tumor volume doubling time. They derived their estimates by calibrating predicted vs actual breast cancer incidence rates from the Surveillance, Epidemiology, and End Results database, and the predicted vs actual distributions of screen-detected tumor sizes using data from the Breast Cancer Surveillance Consortium.

The model showed that younger women had higher estimated mammography thresholds — the smallest tumor diameter that could be detected on mammography — at a median of 1.63 cm for women younger than 40 years, 1.44 cm for women from 40 to 39 years of age, and 1.25 cm for women aged 50 to 59 years. Estimated mean doubling times were 179, 206, and 233 days, respectively.

The researchers then created various hypothetical scenarios to see what would happen if women in their 40s had the doubling times and/or mammography threshold values of women 10 to 20 years older. They found that when the model considered mean tumor size at detection, lifetime gained, and breast cancer mortality, the relative contributions of tumor detectability and doubling time were similar, and that there was a near-linear relationship between screen sensitivity and breast cancer death reduction with annual or biennial screening vs no screening.

However, when they compared screening once yearly to screening once every other year, the researchers found that screening sensitivity was more strongly affected by tumor detectability on mammography than on tumor doubling time.

The journal's editors point out the study's limitations, including the use of estimates that are subject to study biases and that it did not consider the possibility that reduced ability to detect a tumor on mammography could be an independent risk factor associated with a specific breast cancer subtype.

The study was supported by grants from the National Institutes of Health. Author conflicts of interest were not disclosed. Dr. O'Connell has disclosed no relevant financial relationships.

J Natl Cancer Inst. Published online July 27, 2010.